E. Bugge et K. Ytrehus, BRADYKININ PROTECTS AGAINST INFARCTION BUT DOES NOT MEDIATE ISCHEMIC PRECONDITIONING IN THE ISOLATED RAT-HEART, Journal of Molecular and Cellular Cardiology, 28(12), 1996, pp. 2333-2341
The aim of the study was to test if pre-ischemic treatment with bradyk
inin can protect against infarction in an isolated rat heart model of
regional ischemia and reperfusion and if any such protection is depend
ent upon activation of protein kinase C (PKC) or mediated through the
nitric oxide (NO) pathway. Mie also investigated if bradykinin B-2 rec
eptor activation, alone or in combination with activation of adenosine
receptors and a-adrenoceptors, are involved in the infarct size reduc
ing effect of ischemic preconditioning. Buffer-perfused rat hearts wer
e subjected to 30 min regional ischemia and 120 min reperfusion. Risk
zone was determined by fluorescent particles and infarct size by tetra
zolium staining. Treatment with bradykinin (0.5 mu mol/l) prior to isc
hemia significantly reduced infarct size in percentage of risk zone co
mpared to control experiments (infarct size: 9.6 +/- 1.3% v 41.8 +/- 3
.6%, P<0.001). An inhibitor of NO synthesis, NOARG (100 mu mol/l). did
not interfere with the bradykinin induced protection (infarct size: 1
3.3 +/- 2.0%), while chelerythrine (2 mu mol/l), an inhibitor of prote
in kinase C, reversed the effect of bradykinin (infarct size: 30.0 +/-
2.8%). NOARG did not influence infarct size in the control group (inf
arct size: 40.1 +/- 3.2%). Ischemic preconditioning with three cycles
of 5 min global ischemia + 5 min reperfusion offered protection simila
r to bradykinin (infarct size: 8.4 +/- 2.0%). The bradykinin antagonis
t HOE 140 (1 mu mol/l) reversed the effect of bradykinin (infarct size
: 42.5 +/- 3.1%), but did not interfere with ischemic preconditioning
(infarct size: 7.7 +/- 1.6%). Similarily, combined blockade of or-adre
nergic, adenosine and bradykinin B-2 receptors with p-benzamine (10 mu
mol/l), SPT (100 mu mol/l) and HOE 140 did not interfere with ischemi
c preconditioning (infarct size: 7.8 +/- 1.1%). Thus, bradykinin can p
rotect against infarction via protein kinase C, but independently of N
O. A role for bradykinin in mediating ischemic preconditioning against
infarction could not be demonstrated. (C) 1996 Academic Press Limited